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It is shown that the intracellular glutathionc (GSH) concentration of neuroblastoma-h cells in culture increases with 3 maximum at 24 h after 
starting treatment with I-(S-isoquinolinylsulfonyl)-2-methylpipcrazine (H7), an inhibitor of protein kinase C (PKC). Other inhibitors of this and 
other protein hinases, e.g. sphingosinc, staurosporinc, and HA 1004, at the eoncentr?tions tested, bad a less mark& or negligible cffcct on 
intracellular GSH conccntrntion. 12.0.Tetradccanoylphorbol- 13.acetate (TPA) was also tested and jhowcd :lo sigilicant effect 24 h after addition. 
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1. INTRODUCTION 
It has been recently reported that I-(S-isoquino- 
linylsulfonyl)-2-methyl-piperazine, called H?, a known 
inhibitor of protein kinase C (PKC), promoted differen- 
tiation in neuroblastoma-2a cells as indicated by the 
induction of neuritogenesis, increase in acetyl- 
cholinesterase activity [l] and decrease in DNA syn- 
thesis [2]. This effect was reversed by the PKC activator 
12-0-tetradecanoyl- 13.phorbol-acetate (TPA), which 
confirms the involvement of PKC [3]. It has been 
claimed that PKC is sensitive to thiol-disulflde ex- 
change; hence, its activity may be sensitive to the redox 
state of the cellular environment [4]. In the latter report, 
it was discussed that the oxidation state of PKC might 
modillate its activity. In this regard, H402 promoted 
inactivation of partially purified brain PKC [5]; con- 
versely quinone-induced oxygen radical generation lcad 
to activation of the soluble hepatocyte protein to its 
high I’,.,,,, form [4]. 
The main objective of this study was to study the 
changes induced by PKC inhibition on the intracellular 
concentration i  neuro-2a cells of GSH, the most abun- 
dant non-protein thiol in mammalian cells. 
2. MATERIALS AND METHODS 
The clonal line neuro-2a, Cl300 mouse ncurobiz~toma. was ob- 
tainccl from the American Type Culture Collection, Rockvillr, MD, 
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and grown at 37°C in Eagle’s minimum csscntial medium. supple- 
mented with 10% feral bovine serum, 100 IU penicillin/ml, and 1OOyg 
of streptomycin/ml as previously described [2,3]. H7, TPA, stauro- 
sporinc and sphingosine were from Sigma Chemical Co. (St. Louis, 
MO). HA-1004 was from Scikagaku America Inc. (Rockville. MD). 
All reagents were of the highest purity available PKC inhibitors and 
other substances were dissolved in either DMSO or 70% ethanol. 
These solvems had no c!Ycet on cell viability, neuritogencsis. or GSH 
concentration. Cells w.xe seeded at 2oO,tMO/ml and atIer 24 h subcal- 
lure, fresh culture medium containing the inhibitors and/or other 
subslanccs was added. Cell viability was assessed by Trypan blue 
exclusion after detachment. and total GSH conccntntion according 
to [6] and is expressed as GSH equivalents ([GSH] + Z[GSSG]). 
3. RESULTS AND DISCUSSION 
The effe;.t of H7 on GSEi concentration i  neuroblas- 
tom&a cells is shown in Fig. 1; 24 h incubation of 
neuro-2a cells with 0,s mM H7 induced an approxi- 
mately 70% increase in GSH concentration. However, 
unlike neurite outgrowth, which was apparent 4 h after 
starting H7 treatment, no change in GSH concentration 
was observed at this time. With the highest mncentra- 
tion of H7 used, cell viability was not significantly dif- 
ferent from the control (Fig. 2). The fact that GSH 
concentration increases during differentiation fits well 
with previous reports showing changes in GSH during 
the ccl! cycle in different cell lines [7,8]. Moreover, acti- 
vation of cells with TPA in different cellular and in vivo 
models leads to the opposite effect, i.e. decrease of GSG 
concentration [9,10), and also to the release of cell-cell 
contact inhibition [I l]. In order to establish the contri- 
bution of PKC to the changes of G§H concentradon 
observed in Fig. 1, we tested difIizrcnt inhibitors and 
activators of PKC, as well as HA-1004, which inhibits 
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Fig. 1. Effect of H7 on GSH concentration in neurom2a cells after 24 
h treatment. Results are means ?I SE.M. of at least 4 different deter- 
minations. *PcO.OOS, 
the protein kinases dependent on CAMP and cGMP 
with a lower Ki than for PKC [12]. Their effect is shown 
in Table I. Sphingosine and staurosporine, at the con- 
centrations tested, did not affect GSH levels. These in- 
hibitors cannot be tested at higher concentrations be- 
cause they are toxic for the cells. HA-1004 did not affect 
GSH levels, indicating that the effect of H7 is not due 
to inhibition of protein kinasas dependent on CAMP or 
cGMP. TPA did not affect GSH levels in neuro-2a cells. 
The results presented show that the H7-induced dif- 
ferentiation of neuroblastoma cells not only inhibits 
their growth as tumor cells, but results in a high concen- 
tration of GSH. It should be noted that 500 PM H7 is 
needed to induce marked changes in GSH levels. How- 
ever, differentiation of neuro-2a, with stimulation of 
neurite growth, can be observed at much lower doses 
(i.e. 85 ,uM) [l-3]. This indicates that the two phenom- 
ena could not be correlated. It has been shown that 
there is a good correlation between induction of r;curi- 
togenesis by H7 and inhibition cl” protein kinase C [2]. 
The requirement of larger amounts of H7 to induce the 
Table T 
Effect of different inhibitors and activators of protein kinase C on the 
GSH concentration of neuroblastoma-2a cells 
P-.-B 
Addition GSHeq concentration (nmoY 
lob cells) 
-_--- 
None iO.51 ‘r 1.74 (10) 
Sphingosinc 50 PM 12,95 :: 0.54 (4) 
Smurosps:ine 80 nM 11,842 1003 (6) 
HA1004 250,~M 9.67 ? 2.06 (4) 
TPA 25 nM 10.4i k 2.46 (6) 
Results are expressed a.s the mean + SD. with the number of obscrva- 
tions in parenthesis. Additions were made 24 h after subculture, and 
collection of samples 24 h after additions. 
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Fig. 2. Toxicity of H7 on neuro-%a cells after 24 h treatment. 
accumulation of GSH could be attributed to the neces- 
sity of extensive inhibition of PKC or could Indicate 
that the effect is not due to inhibition of PKC. It is 
known that the isoforms of protein kinase C have differ- 
ent responses to activators and inhibitors [13,14] and 
that down-regulation is also different for each isoform 
[15]. Also, the PKC isotypes have differential substrate 
specificity [161 and are involved in different functions 
[17]. It has been reported that only the type II of PKC 
is associated with the membrane skeleton from neu- 
ronal growth cones [18]. Therefore, it is also possible 
that different isoforms of PMC, with very different sus- 
ceptibility to H7 inhibition, could be involved in the 
induction of neuritogenesis and in the control of intra- 
cellular GSH content in this cell type. 
The rise in GSH induced by H7 could be one more 
feature of the morphological (neuri:e outgrowth) and 
functional (acetylcholinesterase ctivity increase) differ- 
entiation of this tumoral cell type observed upon inhibi- 
tion of PKC. The involvement of PKC in the regulation 
of intracellular GSH levels in neural cells has not been 
reported and could be important for the basic under- 
standing of the role of PKC and also could have ther- 
apeutical implications. 
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